Earlier this month, Gilead announced that it will commence Phase I clinical trials for inhaled remdesivir in healthy volunteers, with the aim to extend further studies in patients with Covid-19 in the following months. This follows previous studies highlighting that intravenously administered remdesivir did not provide a meaningful benefit to milder Covid-19 patients. Despite this, an inhaled formulation might work in a different manner.
GlobalData forecasts that the inhaled formulation will target this population, administered by way of a nebuliser for patients to self-administer away from hospitals so staff can prioritise beds for more critical patients. Read more here.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
